The research of Yogish C. Kudva, M.B.B.S., centers on improving existing treatments and developing novel therapies for patients with type 1 diabetes. In particular, Dr. Kudva is interested in developing an effective artificial pancreas system to improve outcomes for patients with type 1 diabetes. Additionally, his research contributes to the creation of new and better cell replacement therapies for patients with type 1 diabetes.
Development of an effective artificial pancreas system for patients with type 1 diabetes. With Ananda Basu, M.B.B.S., M.D., Dr. Kudva has served as a principal investigator of a study — funded by the National Institutes of Health (NIH) — that aims to develop an effective artificial pancreas program using the closed-loop system of continuous glucose sensing and continuous subcutaneous insulin delivery. Drs. Basu and Kudva have also held integral roles in the NIH-funded Artificial Endocrine Pancreas Consortium.
Dr. Kudva is also a co-investigator on a multicenter, multinational NIH-supported study merging physiology, behavior and engineering approaches to accelerate translational research in developing an artificial endocrine pancreas for patients with type 1 diabetes.
- Induced pluripotent stem cell (iPSC) therapy for type 1 diabetes. With Mayo Clinic colleagues James L. Slack, M.D., and Yasuhiro Ikeda, D.V.M., Ph.D., Dr. Kudva has contributed to a partnership between Mayo Clinic and the University of Minnesota to develop islets from iPSCs for treatment of type 1 diabetes.
Significance to patient care
Dr. Kudva has played a key role in the development of the Diabetes Technology Clinic and program, started in 2003 at Mayo Clinic's campus in Rochester, Minnesota. The infrastructure set up by this program resulted in NIH funding for further research in the field of closed-loop (artificial pancreas) therapy for type 1 diabetes. The program is now well-positioned to test the system for weeks to months in the years to come as part of national and international consortia.
Dr. Kudva works closely with Mayo's kidney and pancreas transplant surgical teams to continually improve outcomes of these types of transplant. The transplant program provides long-term insulin independence for more than 60 percent of patients and freedom from hypoglycemia and ketoacidosis for more than 80 percent of patients.
Dr. Kudva collaborates with Mayo's gene therapy and regenerative medicine teams, led by Dr. Ikeda, to develop stem cell therapy for patients with type 1 diabetes.
- Member, International Pancreas and Islet Transplant Association, 2011-present; Fellowship of Royal College of Physicians, 2007-present; American Society of Transplantation, 2005-present
- Institutional Review Board and Research Resources Review Panel, Mayo Clinic, 2009-present
- Transplant Center Research Committee, Mayo Clinic, 2001-present
- Reviewer, Annual Meeting, American Transplant Society, 2008-2015
- Reviewer, Special Emphasis Panel, Human Islet Transplantation and Type 1 Diabetes TrialNet Coordinating Centers, NIH, 2012; Special Emphasis Panel, Islet Transplantation, NIH, 2009 and 2004; Special Emphasis Panel, Diabetes Research Centers, 2007